AU2003217669A1 - A method of recuding anti-neoplastic agent induced side effects - Google Patents

A method of recuding anti-neoplastic agent induced side effects

Info

Publication number
AU2003217669A1
AU2003217669A1 AU2003217669A AU2003217669A AU2003217669A1 AU 2003217669 A1 AU2003217669 A1 AU 2003217669A1 AU 2003217669 A AU2003217669 A AU 2003217669A AU 2003217669 A AU2003217669 A AU 2003217669A AU 2003217669 A1 AU2003217669 A1 AU 2003217669A1
Authority
AU
Australia
Prior art keywords
recuding
side effects
neoplastic agent
induced side
agent induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003217669A
Other languages
English (en)
Other versions
AU2003217669A8 (en
Inventor
Hideo Kikkawa
Mine Kinoshita
Mariko Maeda
Akiko Mizukami
Kazunori Ozawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2003217669A1 publication Critical patent/AU2003217669A1/en
Publication of AU2003217669A8 publication Critical patent/AU2003217669A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2003217669A 2002-02-25 2003-02-21 A method of recuding anti-neoplastic agent induced side effects Abandoned AU2003217669A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35934602P 2002-02-25 2002-02-25
US60/359,346 2002-02-25
PCT/US2003/005482 WO2003072043A2 (fr) 2002-02-25 2003-02-21 Procede de reduction des effets secondaires d'agents anticancereux

Publications (2)

Publication Number Publication Date
AU2003217669A1 true AU2003217669A1 (en) 2003-09-09
AU2003217669A8 AU2003217669A8 (en) 2003-09-09

Family

ID=27766068

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003217669A Abandoned AU2003217669A1 (en) 2002-02-25 2003-02-21 A method of recuding anti-neoplastic agent induced side effects

Country Status (2)

Country Link
AU (1) AU2003217669A1 (fr)
WO (1) WO2003072043A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2486921A1 (fr) * 2007-02-12 2012-08-15 DMI Biosciences, Inc. Réduciton Des Effets Secondaires Du Tramadol
CN109908139B (zh) * 2018-12-28 2022-02-22 南京市儿童医院 西洛司特在制备用于治疗急性肾损伤相关病症的药物中的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156753A (en) * 1997-10-28 2000-12-05 Vivus, Inc. Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction

Also Published As

Publication number Publication date
WO2003072043A2 (fr) 2003-09-04
WO2003072043A3 (fr) 2004-03-04
AU2003217669A8 (en) 2003-09-09

Similar Documents

Publication Publication Date Title
AU2003276045A1 (en) Method of solving a split-brain condition
AU2003207660A1 (en) Method of landing items at a well location
AU2003277596A1 (en) Method of deuterization
AUPS160602A0 (en) Therapeutic method
AU2003256526A1 (en) Arrangements and methods for treating a subject
AU2003290818A1 (en) Topoisomerase-targeting agents
AU2003217669A1 (en) A method of recuding anti-neoplastic agent induced side effects
AU2002349470A1 (en) A method and unit for multi-user interference cancellation
EP1337138A3 (fr) Structure de maintien de composants coupés et procédé de son lavage
AU2003263285A1 (en) Method of maintaining a measuring
AU2003258982A1 (en) Methods of inhibiting pin1-associated states using a fredericamycin a compound
AUPS230702A0 (en) A method of treatment
AU2003293581A1 (en) Method of identifying therapeutic agents
AU2003281152A1 (en) A method for inhibiting vascular permeability and tissue edema
AU2003905109A0 (en) A method of treatment and agents useful for same
AU2003900729A0 (en) A method of treatment and agents useful for same
AU2003260322A1 (en) Nolomirole hydrochloride form i
AU2002952098A0 (en) A method of treatment and agents useful for same-ii
AUPS069202A0 (en) A method of treatment
AU2002952658A0 (en) A method of treatment
AU2002331824A1 (en) Method of protecting a surface
AU2003280609A1 (en) Alpha-GLUCOSIDASE INHIBITOR
AU2002952057A0 (en) A method and agents useful for same
AU2002950745A0 (en) A method and agents useful for same
AU2003249784A1 (en) A method and agents useful for same

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase